Yes I appreciate the difference between cashflow and EBITDA, but I am seeing a H1 FY23 cash outflow of -$128k for operating activities and ~$3m outflow for development costs that have been capitalized, so I figured the company would be close to cashflow positive based on the recent sales or at the very least that operating activities would be funding the development.
Has management ever come out and talked about the development costs and where they will sit on a normalized basis ? It is hard to know if that is BAU development or if is for a specific bit of tech / software the company is hoping to build out.
- Forums
- ASX - By Stock
- EVS
- Ann: Q4 Sales Update - Record Quarter $6.8m New Sales
EVS
envirosuite limited
Add to My Watchlist
2.50%
!
8.2¢

Ann: Q4 Sales Update - Record Quarter $6.8m New Sales, page-20
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
8.2¢ |
Change
0.002(2.50%) |
Mkt cap ! $118.8M |
Open | High | Low | Value | Volume |
8.0¢ | 8.2¢ | 8.0¢ | $196.0K | 2.425M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 179727 | 8.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.3¢ | 209692 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 179727 | 0.082 |
1 | 1790783 | 0.081 |
3 | 665259 | 0.080 |
2 | 1468871 | 0.079 |
3 | 698163 | 0.078 |
Price($) | Vol. | No. |
---|---|---|
0.083 | 79192 | 1 |
0.084 | 260627 | 6 |
0.085 | 874469 | 10 |
0.086 | 2030000 | 2 |
0.087 | 694750 | 2 |
Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
Featured News
EVS (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online